Methodological challenges in determining longitudinal associations between anticholinergic drug use and incident cognitive decline

Journal of the American Geriatrics Society

Volumn 62, Issue 2, 2014, Pages 336-341

  Kashyap, Mandavi ^a   Belleville, Sylvie ^a   Mulsant, Benoit H ^b   Hilmer, Sarah N ^c   Paquette, Amelie ^a   Tu, Le Mai ^d   Tannenbaum, Cara ^a  

^a CENTRE DE RECHERCHE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY INSTITUTE OF GERIATRICS OF SHERBROOKE   (Canada)

Author keywords

anticholinergic drug exposure; cognitive decline; longitudinal study; methods; older adults

Indexed keywords

ANTICHOLINERGIC DRUG EXPOSURE; COGNITIVE DECLINE; LONGITUDINAL STUDY; METHODS; OLDER ADULTS;

AGED; AGED, 80 AND OVER; CHOLINERGIC ANTAGONISTS; COGNITION; COGNITION DISORDERS; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; ODDS RATIO; OUTPATIENTS; QUEBEC;

EID: 84894050781     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.12632     Document Type: Article

References (26)

1. Terry AV Jr, Buccafusco JJ,. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003; 306: 821-827.
2. Paquette A, Gou P, Tannenbaum C,. Systematic review and meta-analysis: Do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J Am Geriatr Soc 2011; 59: 1332-1339.
3. Wagg A, Dale M, Tretter R, et al. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: The SENIOR Study. Eur Urol 2013; 64: 74-81.
4. Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: Longitudinal cohort study. BMJ 2006; 332: 455-458.
5. Carriere I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: The 3-City Study. Arch Intern Med 2009; 169: 1317-1324.
6. Campbell NL, Boustani MA, Lane KA, et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology 2010; 75: 152-159.
7. Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: The Medical Research Council Cognitive Function and Ageing Study. J Am Geriatr Soc 2011; 59: 1477-1483.
8. Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007; 167: 781-787.
9. Rudolph JL, Salow MJ, Angelini MC, et al. The Anticholinergic Risk Scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008; 168: 508-513.
10. Carnahan RM, Lund BC, Perry PJ, et al. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: Associations with serum anticholinergic activity. J Clin Pharmacol 2006; 46: 1481-1486.
11. Boustani M, Campbell N, Munger S, et al. Impact of anticholinergics on the aging brain: A review and practical application. Aging Health 2008; 4: 311-320.
12. Strauss E, Sherman EMS, Spreen O,. A Compendium of Neuropsychological Tests. Administration, Norms and Commentary, 3rd Ed. New York: Oxford University Press, 2006.
13. Hermann BP, Seidenberg M, Schoenfeld J, et al. Empirical techniques for determining the reliability, magnitude, and pattern of neuropsychological change after epilepsy surgery. Epilepsia 1996; 37: 942-950.
14. Sawrie SM, Marson DC, Boothe AL, et al. A method for assessing clinically relevant individual cognitive change in older adult populations. J Gerontol B Psychol Sci Soc Sci 1999; 54B: P116-P124.
15. Sawrie SM,. Analysis of cognitive change: A commentary on Keith et al. Neuropsychology 2002; 16: 429-431.
16. Sawrie MS, Chelune GJ, Naugle RI, et al. Empirical methods for assessing meaningful change following epilepsy surgery. J Int Neuropsychol Soc 1996; 2: 556-564.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. Arlington, VA: American Psychiatric Association, 2013.
18. Lindeboom J, Folstein MF, Folstein SE, et al. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
19. Montorio I, Izal M,. The Geriatric Depression Scale: A review of its development and utility. Int Psychogeriatr 1996; 8: 103-112.
20. CPS. Compendium of Pharmaceuticals and Specialties. Toronto, Canada: Canadian Pharmacists Association, Webcom Inc., 2012.
21. Van der Linden M, Wyns C, Coyette F, et al. Questionnaire d'Auto-Évaluation de la Mémoire. Bruxelles, Belgique: Editest, 1989.
22. Desrosiers J, Bravo G, Hebert R, et al. Reliability of the revised functional autonomy measurement system for epidemiological research. Age Ageing 1995; 24: 402-406.
23. Clement F, Belleville S, Gauthier S,. Cognitive complaints in mild cognitive impairment and Alzheimer's disease. J Int Neuropsychol Soc 2008; 14: 222-232.
24. McAlister FA, Straus SE, Guyatt GH, Haynes RB,. Users' guide to the medical literature. Integrating research evidence with the care of the individual patient. JAMA 2000; 283: 2829-2836.
25. Nebes RD, Pollock BG, Houck PR, et al. Persistence of cognitive impairment in geriatric patients following antidepressant treatment: A randomized, double-blind clinical trial with nortriptyline and paroxetine. J Psychiatr Res 2003; 37: 99-108.
26. Nishiya K, Momoseb T, Sugishitac M, et al. Positron emission tomography of reversible intellectual impairment induced by long-term anticholinergic therapy. J Neurol Sci 1995; 132: 89-92.